Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, December 21, 2023
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
[ Thu, Dec 21st 2023
] - WOPRAI
Wed, December 20, 2023
[ Wed, Dec 20th 2023
] - WOPRAI
[ Wed, Dec 20th 2023
] - WOPRAI
[ Wed, Dec 20th 2023
] - WOPRAI
[ Wed, Dec 20th 2023
] - WOPRAI
[ Wed, Dec 20th 2023
] - WOPRAI
[ Wed, Dec 20th 2023
] - WOPRAI
Kelly Shi Initiated (ASND) at Strong Buy and Held Target at $150 on, Dec 20th, 2023
Kelly Shi of Jefferies, Initiated "Ascendis Pharma A/S" (ASND) at Strong Buy and Held Target at $150 on, Dec 20th, 2023.
Kelly has made no other calls on ASND in the last 4 months.
There are 2 other peers that have a rating on ASND. Out of the 2 peers that are also analyzing ASND, 1 agrees with Kelly's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $116 on, Thursday, November 9th, 2023
This is the rating of the analyst that currently disagrees with Kelly
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $149 on, Tuesday, December 19th, 2023
